Dataset Information


Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.

ABSTRACT: Kinase inhibitors constitute an important new class of cancer drugs, whose selective efficacy is largely determined by underlying tumor cell genetics. We established a high-throughput platform to profile 500 cell lines derived from diverse epithelial cancers for sensitivity to 14 kinase inhibitors. Most inhibitors were ineffective against unselected cell lines but exhibited dramatic cell killing of small nonoverlapping subsets. Cells with exquisite sensitivity to EGFR, HER2, MET, or BRAF kinase inhibitors were marked by activating mutations or amplification of the drug target. Although most cell lines recapitulated known tumor-associated genotypes, the screen revealed low-frequency drug-sensitizing genotypes in tumor types not previously associated with drug susceptibility. Furthermore, comparing drugs thought to target the same kinase revealed striking differences, predictive of clinical efficacy. Genetically defined cancer subsets, irrespective of tissue type, predict response to kinase inhibitors, and provide an important preclinical model to guide early clinical applications of novel targeted inhibitors.


PROVIDER: S-EPMC2148401 | BioStudies | 2007-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC6089937 | BioStudies
2016-01-01 | S-EPMC4802229 | BioStudies
2020-01-01 | S-EPMC7664030 | BioStudies
2013-01-01 | S-EPMC3873899 | BioStudies
2017-01-01 | S-EPMC6433282 | BioStudies
2019-01-01 | S-EPMC6498855 | BioStudies
2020-01-01 | S-EPMC7136923 | BioStudies
2021-10-28 | GSE186341 | GEO
2016-01-01 | S-EPMC5029658 | BioStudies
2015-01-01 | S-EPMC4297247 | BioStudies